SynthesisFrontiers in endocrinology2021
Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study.
Synthesis in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Review
- Venous Thromboembolism in Transgender and Gender Diverse Individuals on Estrogen-Based Gender-Affirming Hormone Therapy.Journal of clinical medicine · 2026Article
- Contemporary Challenges in Venous Thromboembolism: Evolving Populations and Implications for Management and Risk Stratification.Journal of clinical medicine · 2026Review
- Structure and hormonal output of the adrenal gland after experimental estrogenization of male rats.Histology and histopathology · 2025Article
- Postoperative venous thromboembolism in transgender patients receiving estrogen-based hormone therapy.Research and practice in thrombosis and haemostasis · 2025Article
- Hemostatic parameters in transgender women receiving gender-affirming hormone therapy: A shift to a cisgender female pattern?PloS one · 2025Article
- Gender-affirming hormone therapy in the transgender patient: influence on thrombotic risk.Hematology. American Society of Hematology. Education Program · 2024Review
- Gender Reassignment and the Role of the Laboratory in Monitoring Gender-Affirming Hormone Therapy.Journal of clinical medicine · 2024Review
- Cerebral venous sinus thrombosis: changing trends in the incidence, age and gender (findings from the CMC Vellore CVT registry).Stroke and vascular neurology · 2024Article
- Approach to the Patient: Hormonal Therapy in Transgender Adults With Complex Medical Histories.The Journal of clinical endocrinology and metabolism · 2024Article
- LGBTQ+ cardiovascular health equity: a brief review.Frontiers in cardiovascular medicine · 2024Review
- Insights Into the Cardiomodulatory Effects of Sex Hormones: Implications in Transgender Care.Hypertension (Dallas, Tex. : 1979) · 2023Review
- Cardiovascular disease and feminizing gender-affirming hormone therapy: Implications for the provision of safe and lifesaving care.Current opinion in physiology · 2023Article
- Heart-Kidney Transplantation in a Transgender Woman.JACC. Case reports · 2022Article
- Psychopharmacological Considerations for Gender-Affirming Hormone Therapy.Harvard review of psychiatryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although venous thromboembolism (VTE) is a recognized side effect of some formulations of estrogen therapy, its impact in transgender people remains uncertain. The aim of this study was to define pooled prevalence estimate and correlates of VTE in Assigned Males at Birth (AMAB) trans people undergoing gender affirming hormone therapy. Methods: A thorough search of MEDLINE, COCHRANE LIBRARY, SCOPUS and WEB OF SCIENCE databases was carried out to identify suitable studies. Quality of the articles was scored using the Assessment Tool for Prevalence Studies. Data were combined using random effects models and the between-study heterogeneity was assessed by the Cochrane's Q and I Results: The eighteen studies included gave information about 11,542 AMAB undergoing gender affirming hormone therapy. The pooled prevalence of VTE was 2% (95%CI:1-3%), with a large heterogeneity (I Conclusions: The overall rate of VTE in AMAB trans people undergoing gender affirming hormone therapy was 2%. In AMAB population with <37.5 years undergoing estrogen therapy for less than 53 months, the risk of VTE appears to be negligible. Further studies are warranted to assess whether different types and administration routes of estrogen therapy could decrease the VTE risk in AMAB trans people over 37.5 years subjected to long-term therapy. Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42021229916].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.